市場調査レポート

商品コード

がんのガンマ・デルタT細胞療法の世界市場：市場動向、技術プラットフォーム、臨床試験の見通し（2031年）

Global Gamma Delta T Cell Cancer Therapy Market Trends, Technology Platforms & Clinical Trials Outlook 2031

出版日: 2025年06月01日
発行: KuicK Research
ページ情報: 英文 210 Pages
納期: 即日から翌営業日

価格

PDF (Single User License)

USD 3,000 438,180円

レポートPDFを1名のみがご利用頂けるライセンスです。 PDF内のテキスト等のコピー＆ペーストは出来ません。 PDFの印刷は一度のみ可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Multi-User License)

USD 5,100 744,906円

レポートPDFを貴社内のすべての方にご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=146.06円

ご注意:　DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界のがんのガンマ・デルタT細胞療市場動向、技術プラットフォーム、臨床試験の見通し（2031年）レポートの結論

臨床試験中のがんのガンマ・デルタT細胞療：>25以上の治療法
最も高い開発段階：第II/III相
2025年6月現在、ガンマ・デルタT細胞療法は市販されていない
米国と中国がガンマ・デルタT細胞療法の臨床試験を支配している：20以上の治療法
ガンマ・デルタT細胞療法の臨床試験インサイト：企業、国、適応症、相別
ガンマ・デルタT細胞療法技術プラットフォームの企業別インサイト：15プラットフォーム以上
ガンマ・デルタT細胞療法の適応症別市場のポテンシャル

アドプティブ・ガンマ・デルタ（Yδ）T細胞療法は、T細胞のユニークなサブセットを利用してがん細胞を認識・破壊する新しいタイプの免疫療法です。典型的なαβ（aB）T細胞が主要組織適合複合体（MHC）分子によって提示される抗原を識別するのに対し、YδT細胞はMHCに依存しない様式でストレス誘導リガンドやリン酸化抗原によって活性化されます。このため、従来の免疫警戒では標的とされなかった腫瘍も含め、多種多様な腫瘍を検出し、標的とすることができます。YδT細胞は自然免疫と適応免疫の両方の特徴を持ち、即時反応と免疫記憶の能力を持つことができるため、市販の養子細胞療法の候補として特に適しています。

がんにおいては、YδT細胞は、技術的に困難で高価な腫瘍特異的抗原や遺伝子改変を必要とせずに、悪性細胞を破壊する可能性について研究されています。その本質的な細胞傷害性は、（健康なドナーからの）同種細胞利用の可能性とともに、大量生産可能で安価な治療法へのアクセスを提供します。現在までの臨床研究開発の大部分は血液悪性腫瘍で行われており、特に有望視されています。YδT細胞は骨髄や他のリンパ系臓器に侵入し、サイトカインの放出、直接的な細胞傷害性、腫瘍の微小環境の変化を通じて腫瘍に影響を及ぼすことができます。

特に急性骨髄性白血病（AML）のような血液がんでは、再発しやすい、あるいは従来の治療法に抵抗性を示す傾向があり、新規のがん治療法に対する需要は切迫しています。寛解後に再発した患者や残存病変（MRD）を有する患者に対する選択肢は限られており、予後は通常不良です。YδT細胞療法は、このギャップを埋めるユニークな位置にあり、潜在的に有効で、安全で、製造上の保留や患者のばらつきなど、自家T細胞療法の物流上の問題なしに提供可能な既製品を提供します。

TC Biopharmは、この分野の臨床開発をリードしています。同社の最先端の製品候補であるOmnImmune（旧TCB-002）は、AMLを対象とした極めて重要な第II/III相試験中です。OmnImmuneは同種YδT細胞療法で、正常組織へのダメージを避けながら、がん細胞を素早く標的にして破壊するように設計されています。この臨床プログラムは、世界のYδT細胞パイプラインの中で最も進んだもの一つであり、TC Biopharmがこの領域でリーダーシップを発揮しつつあることを強調しています。OmnImmune以外にも、同社は様々ながんの適応症で開発中のYδT細胞候補を数多く有しています。

TC Biopharmの最近の動向で最も重要なものひとつは、第2相ACHIEVE試験で調査中のTCB008候補の開発です。同社は2025年6月、検出可能なMRDを有する以前に再発したコホートBの最初の患者が、2回の投与で完全分子寛解に達したことを報告しました。治療後にNPM1転写物が検出されないことは、深い持続的な奏効を意味し、TCB008が血液がんの寛解後治療薬として有望であることを示すものです。この成果は、YδT細胞の強力な標的免疫機能を明確にし、新たな治療戦略としての役割を実証するものです。

世界的に見ると、YδT細胞に関する調査のほとんどは血液悪性腫瘍にとどまっており、固形腫瘍を対象としたプログラムは少なくなっています。これは、固形がんがより洗練された微小環境と免疫回避機構を利用するためでもあります。しかし、YδT細胞治療をこのようなより困難な状況に適用しようとする試みは行われています。地域的には、米国を拠点とする企業がYδT細胞治療市場を独占しており、次いで中国企業の数が増加しています。これらの地域は細胞治療施設や技術に多額の投資を行っており、ベンチからベッドサイドへの迅速な移行を促進しています。

今後、YδT細胞療法の見通しは明るいが、固形がんを対象とした臨床的検証を継続する必要があります。製造技術とバイオマーカー主導型戦略の進歩により、YδT細胞の使用はより多くの種類のがんに拡大する可能性があります。TC Biopharmのようなリーダーが最前線にいることで、この分野は、がん領域における重要なアンメットニーズに対して、人生を変える治療を提供する軌道に乗っています。

List of Figures

Figure 1-1: History Of T Cell Based Immunotherapy
Figure 1-2: Gamma Delta T cell Therapy
Figure 1-3: Stimulants of Gamma Delta T Cells
Figure 1-4: CAR T Cell Therapy Limitations
Figure 1-5: Limitations of TIL
Figure 1-6: Limitations of Monoclonal Antibodies
Figure 1-7: Drawbacks of Chemotherapeutic Drugs
Figure 2-1: Pro-Tumor Role of Gamma Delta T Cells
Figure 2-2: Antigen Presentation Functions Of Gamma Delta T Cells
Figure 2-3: Anti-Tumor Activity of Gamma Delta T-Cells
Figure 2-4: Gamma Delta T Cell Bispecific Antibodies - Mechanism of Action
Figure 2-5: Functional Advantages Of Yo T Cells for CAR T Cancer Therapy
Figure 2-6: CAR Yo T Cells - Mechanism of Action
Figure 4-1: Gamma Delta T Cell Therapy Market - Future Opportunities
Figure 4-2: Global - Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-3: Global - Gamma Delta T Cell Therapy Market Opportunity By 1% Of Total Cell Therapy Market (US$ Billion), 2025 -2031
Figure 4-4: Global - Gamma Delta T Cell Therapy Market Opportunity By 2% Of Total Cell Therapy Market (US$ Billion), 2025 -2031
Figure 4-5: Global - Gamma Delta T Cell Therapy Market Opportunity By 3% Of Total Cell Therapy Market (US$ Billion), 2025 -2031
Figure 4-6: Global - Gamma Delta T Cell Therapy Market Opportunity By 4% Of Total Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-7: Global - Gamma Delta T Cell Therapy Market Opportunity By 5% Of Total Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-8: Global - Gamma Delta T Cell Therapy Market Opportunity By 6% Of Total Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-9: Global - Gamma Delta T Cell Therapy Market Opportunity By 7% Of Total Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-10: Global - Gamma Delta T Cell Therapy Market Opportunity By 8% Of Total Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-11: Global - Gamma Delta T Cell Therapy Market Opportunity By 9% Of Total Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-12: Global - Gamma Delta T Cell Therapy Market Opportunity By 10% Of Total Cell Therapy Market (US$ Billion), 2025 - 2031
Figure 4-13: IN8bio - DeltEx DRI Auto
Figure 4-14: Diamond AI - Prediction Engine
Figure 4-15: Diamond AI - Immune Surveillance
Figure 4-16: Acepodia - Antibody-Cell Conjugation
Figure 4-17: Lava Therapeutics - Gammabody Platform
Figure 4-18: Adicet Bio - Gamma Delta Cell Platform
Figure 4-19: ADI-001 - Gamma Delta Cell Therapy
Figure 4-20: Century Therapeutics - Allo-Evasion
Figure 4-21: ViGenCell - ViRanger Platform
Figure 4-22: Legend Biotech - CAR-Yo T Platform
Figure 4-23: Immatics - ACTallo(R) Manufacturing Process
Figure 4-24: Gamma Delta T Cell Platform - carxall
Figure 4-25: Proprietary Manufacturing & Cell Platform Process - Adicet Bio
Figure 4-26: CAR-Yo T Cell - CytoMed Therapeutics
Figure 4-27: iPSC-Yo NKT Cells - CytoMed Therapeutics
Figure 4-28: Luminary Therapeutics - TcBuster Benefits
Figure 4-29: SSC Cell Platform - Core Foundations
Figure 4-30: Acua Platform - Appia Bio
Figure 4-31: Gamma Delta T Cell Therapy Market Drivers & Opportunities
Figure 4-32: Gamma Delta T Cell Therapy Market Challenges & Restraints
Figure 5-1: Global - Gamma Delta T Cell Therapy Clinical Trials By Phase (Numbers), 2025 Till 2031
Figure 5-2: Global - Gamma Delta T Cell Therapy Clinical Trials By Country (Numbers), 2025 Till 2031
Figure 5-3: Global - Gamma Delta T Cell Therapy Clinical Trials By Company (Numbers), 2025 Till 2031
Figure 5-4: Global - Gamma Delta T Cell Therapy Clinical Trials By Indication (Numbers), 2025 Till 2031
Figure 5-5: Global - Gamma Delta T Cell Therapy Clinical Trials By Priority Status (Numbers), 2025 Till 2031
Figure 7-1: Benefits of Gamma Delta T Cells in Leukemia
Figure 7-2: CD33CART Phase 1/2 (NCT03971799) Study - Initiation & Completion Year
Figure 7-3: ACHIEVE (TCB008-001) Phase 2 (NCT05358808) Study - Initiation & Completion Year
Figure 7-4: ACHIEVE2 (TCB008-003) Phase 1 (NCT06463327) Study - Initiation & Completion Year
Figure 7-5: INB-100 Phase 1 (NCT03533816) Study - Initiation & Completion Year
Figure 7-6: Mechanism of Action of VY9/CD123 Bispecific Antibody
Figure 7-7: Global - Estimated Leukemia Cases, 2025-2031
Figure 7-8: US - Estimated Leukemia Cases, 2025-2031
Figure 7-9: Europe - Estimated Leukemia Cases, 2025-2031
Figure 7-10: China - Estimated Leukemia Cases, 2025-2031
Figure 7-11: Japan - Estimated Leukemia Cases, 2025-2031
Figure 8-1: Role of Gamma Delta T Cells in Lung Cancer
Figure 8-2: DELTACEL-01 Phase 1 (NCT06069570) Study - Initiation & Completion Year
Figure 8-3: Global - Estimated Lung Cancer Cases, 2025-2031
Figure 8-4: US - Estimated Lung Cancer Cases, 2025-2031
Figure 8-5: Europe - Estimated Lung Cancer Cases, 2025-2031
Figure 8-6: China - Estimated Lung Cancer Cases, 2025-2031
Figure 8-7: Japan - Estimated Lung Cancer Cases, 2025-2031
Figure 9-1: Global - Estimated Breast Cancer Cases, 2025-2031
Figure 9-2: US - Estimated Breast Cancer Cases, 2025-2031
Figure 9-3: Europe - Estimated Breast Cancer Cases, 2025-2031
Figure 9-4: China - Estimated Breast Cancer Cases, 2025-2031
Figure 9-5: Japan - Estimated Breast Cancer Cases, 2025-2031
Figure 10-1: Role of Gamma Delta T Cells in Colorectal Cancer
Figure 10-2: Mechanism Underlying B7-H3 Regulating Yo T Cells Killing Colon Cancer Cells
Figure 10-3: SGNEGFRd2-001 Phase I (NCT05983133) Study - Initiation & Completion Year
Figure 10-4: Global - Estimated Colorectal Cancer Cases, 2025-2031
Figure 10-5: US - Estimated Colorectal Cancer Cases, 2025-2031
Figure 10-6: Europe - Estimated Colorectal Cancer Cases, 2025-2031
Figure 10-7: China - Estimated Colorectal Cancer Cases, 2025-2031
Figure 10-8: Japan - Estimated Colorectal Cancer Cases, 2025-2031
Figure 11-1: Auspicious Outcomes Gamma Delta T Cell Therapy
Figure 11-2: Role of Gamma Delta T Cells in Pancreatic Cancer Progression
Figure 11-3: Global - Estimated Pancreatic Cancer Cases, 2025-2031
Figure 11-4: US - Estimated Pancreatic Cancer Cases, 2025-2031
Figure 11-5: Europe - Estimated Pancreatic Cancer Cases, 2025-2031
Figure 11-6: China - Estimated Pancreatic Cancer Cases, 2025-2031
Figure 11-7: Japan - Estimated Pancreatic Cancer Cases, 2025-2031
Figure 12-1: ACE1831 Phase I (NCT05653271) Study - Initiation & Completion Year
Figure 12-2: ADI-001 Phase I (NCT04735471) Study - Initiation & Completion Year
Figure 12-3: Global - Estimated Lymphoma Cases, 2025-2031
Figure 12-4: US - Estimated Lymphoma Cases, 2025-2031
Figure 12-5: Europe - Estimated Lymphoma Cases, 2025-2031
Figure 12-6: China - Estimated Lymphoma Cases, 2025-2031
Figure 12-7: Japan - Estimated Lymphoma Cases, 2025-2031
Figure 13-1: INB-400 Phase 1/2 (NCT05664243) Study - Initiation & Completion Year
Figure 13-2: IN8bio - Autologous (INB-400) & Allogeneic (INB-410) Candidates
Figure 13-3: UAB 1773 Phase 1 (NCT04165941) Study - Initiation & Completion Year
Figure 13-4: Global - Estimated Brain Cancer Cases, 2025-2031
Figure 13-5: US - Estimated Brain Tumor Cases, 2025-2031
Figure 13-6: Europe - Estimated Brain Tumor Cases, 2025-2031
Figure 13-7: China - Estimated Brain Tumor Cases, 2025-2031
Figure 13-8: Japan - Estimated Brain Tumor Cases, 2025-2031
Figure 14-1: Acepodia Biotech Clinical Pipeline Insight
Figure 14-2: Pfizer & Lava Therapeutics Collaboration
Figure 14-3: SGN-EGFRd2 Phase 1 (NCT05983133) Study - Initiation & Completion Year
Figure 14-4: Global - Estimated Head & Neck Cancer Cases, 2025-2031
Figure 14-5: US - Estimated Head & Neck Cancer Cases, 2025-2031
Figure 14-6: Europe - Estimated Head & Neck Cancer Cases, 2025-2031
Figure 14-7: China - Estimated Head & Neck Cancer Cases, 2025-2031
Figure 14-8: Japan - Estimated Head & Neck Cancer Cases, 2025-2031

List of Tables

Table 3-1: Ongoing Clinical Trials For Combination Of Gamma Delta T Cell Therapy
Table 7-1: Global - Estimated Adoption Rate Of Gamma Delta T Cell In Leukemia, 2025-2031
Table 7-2: US - Estimated Adoption Rate Of Gamma Delta T Cell In Leukemia, 2025-2031
Table 7-3: Europe - Estimated Adoption Rate Of Gamma Delta T Cell In Leukemia, 2025-2031
Table 7-4: China - Estimated Adoption Rate Of Gamma Delta T Cell In Leukemia, 2025-2031
Table 7-5: Japan - Estimated Adoption Rate Of Gamma Delta T Cell In Leukemia, 2025-2031
Table 8-1: Global - Estimated Adoption Rate Of Gamma Delta T Cell In Lung Cancer, 2025-2031
Table 8-2: US - Estimated Adoption Rate Of Gamma Delta T Cell In Lung Cancer, 2025-2031
Table 8-3: Europe - Estimated Adoption Rate Of Gamma Delta T Cell In Lung Cancer, 2025-2031
Table 8-4: China - Estimated Adoption Rate Of Gamma Delta T Cell In Lung Cancer, 2025-2031
Table 8-5: Japan - Estimated Adoption Rate Of Gamma Delta T Cell In Lung Cancer, 2025-2031
Table 9-1: Global - Estimated Adoption Rate Of Gamma Delta T Cell In Breast Cancer, 2025-2031
Table 9-2: US - Estimated Adoption Rate Of Gamma Delta T Cell In Breast Cancer, 2025-2031
Table 9-3: Europe - Estimated Adoption Rate Of Gamma Delta T Cell In Breast Cancer, 2025-2031
Table 9-4: China - Estimated Adoption Rate Of Gamma Delta T Cell In Breast Cancer, 2025-2031
Table 9-5: Japan - Estimated Adoption Rate Of Gamma Delta T Cell In Breast Cancer, 2025-2031
Table 10-1: Global - Estimated Adoption Rate Of Gamma Delta T Cell In Colorectal Cancer, 2025-2031
Table 10-2: US - Estimated Adoption Rate Of Gamma Delta T Cell In Colorectal Cancer, 2025-2031
Table 10-3: Europe - Estimated Adoption Rate Of Gamma Delta T Cell In Colorectal Cancer, 2025-2031
Table 10-4: China - Estimated Adoption Rate Of Gamma Delta T Cell In Colorectal Cancer, 2025-2031
Table 10-5: Japan - Estimated Adoption Rate Of Gamma Delta T Cell In Colorectal Cancer, 2025-2031
Table 11-1: Global - Estimated Adoption Rate Of Gamma Delta T Cell In Pancreatic Cancer, 2025-2031
Table 11-2: US - Estimated Adoption Rate Of Gamma Delta T Cell In Pancreatic Cancer, 2025-2031
Table 11-3: Europe - Estimated Adoption Rate Of Gamma Delta T Cell In Pancreatic Cancer, 2025-2031
Table 11-4: China - Estimated Adoption Rate Of Gamma Delta T Cell In Pancreatic Cancer, 2025-2031
Table 11-5: Japan - Estimated Adoption Rate Of Gamma Delta T Cell In Pancreatic Cancer, 2025-2031
Table 12-1: Global - Estimated Adoption Rate Of Gamma Delta T Cell In Lymphoma, 2025-2031
Table 12-2: US - Estimated Adoption Rate Of Gamma Delta T Cell In Lymphoma, 2025-2031
Table 12-3: Europe - Estimated Adoption Rate Of Gamma Delta T Cell In Lymphoma, 2025-2031
Table 12-4: China - Estimated Adoption Rate Of Gamma Delta T Cell In Lymphoma, 2025-2031
Table 12-5: Japan - Estimated Adoption Rate Of Gamma Delta T Cell In Lymphoma, 2025-2031
Table 13-1: Global - Estimated Adoption Rate Of Gamma Delta T Cell In Brain Tumors, 2025-2031
Table 13-2: US - Estimated Adoption Rate Of Gamma Delta T Cell In Brain Tumors, 2025-2031
Table 13-3: Europe - Estimated Adoption Rate Of Gamma Delta T Cell In Brain Tumors, 2025-2031
Table 13-4: China - Estimated Adoption Rate Of Gamma Delta T Cell In Brain Tumors, 2025-2031
Table 13-5: Japan - Estimated Adoption Rate Of Gamma Delta T Cell In Brain Tumors, 2025-2031
Table 14-1: Global - Estimated Adoption Rate Of Gamma Delta T Cell In Head & Neck Cancers, 2025-2031
Table 14-2: US - Estimated Adoption Rate Of Gamma Delta T Cell In Head & Neck Cancers, 2025-2031
Table 14-3: Europe - Estimated Adoption Rate Of Gamma Delta T Cell In Head & Neck Cancer, 2025-2031
Table 14-4: China - Estimated Adoption Rate Of Gamma Delta T Cell In Head & Neck Cancers, 2025-2031
Table 14-5: Japan - Estimated Adoption Rate Of Gamma Delta T Cell In Head & Neck Cancer, 2025-2031

Global Gamma Delta T Cell Cancer Therapy Market Trends, Technology Platforms & Clinical Trials Outlook 2031 Report Conclusions:

Gamma Delta T Cell Therapies In Clinical Trials: > 25 Therapies
Highest Phase Of Development: Phase II/III
As Of June'2025 No Gamma Delta T Cells Therapy Is Commercially Available
US & China Dominating Gamma Delta T Cell Therapies Clinical Trials Landscape: > 20 Therapies
Gamma Delta T Cell Therapy Clinical Trials Insight By Company, Country, Indication and Phase
Gamma Delta T Cell Therapies Technology Platforms Insight By Company : > 15 Platforms
Gamma Delta T Cell Therapy Market Potential By Indications Based On Adoption Rates

Adoptive gamma delta (Yδ) T cell therapy is a novel type of immunotherapy that utilizes a unique subset of T cells to recognize and destroy cancer cells. While typical alpha-beta (aB) T cells identify antigens presented by major histocompatibility complex (MHC) molecules, Yδ T cells are activated by stress induced ligands and phosphoantigens in an MHC independent fashion. This enables them to detect and target a wide variety of tumor types, including those that are not targeted by conventional immune vigilance. Yδ T cells possess characteristics of both innate and adaptive immunity, allowing them to have the ability for immediate response and immune memory, which make them particularly good candidates for off-the-shelf adoptive cell therapies.

In cancer, Yδ T cells are under investigation for their potential to destroy malignant cells without the requirement of tumor-specific antigens or genetic modifications, which are technically demanding and expensive. Their intrinsic cytotoxicity, along with the possibility of allogeneic utilization (from healthy donors), provides access to the availability of mass producible, inexpensive therapies. The majority of clinical research and development to date has been in hematological malignancies, where they have been especially promising. Yδ T cells are able to penetrate the bone marrow and other lymphoid organs and exert tumor effects there through cytokine release, direct cytotoxicity, and changing the microenvironment of the tumor.

The demand for novel cancer therapies is pressing, especially in blood cancers like acute myeloid leukemia (AML), which tend to relapse or are resistant to conventional therapies. Options for patients who relapse following remission or who have residual disease (MRD) are limited, and prognosis is usually poor. Yδ T cell therapies are in a unique position to bridge this gap, providing a potentially effective, safe, and off-the-shelf product that can be delivered without the logistical issues of autologous T cell therapies, including manufacturing hold-ups or patient variability.

TC Biopharm is leading the way in clinical development in this area. The company's most advanced product candidate, OmnImmune (formerly TCB-002), is in a pivotal Phase 2/3 trial for AML. OmnImmune is an allogeneic Yδ T cell therapy engineered to quickly target and destroy cancer cells while avoiding damage to normal tissue. This clinical program is one of the most advanced in the global Yδ T cell pipeline, highlighting TC Biopharm's growing leadership within the domain. Besides OmnImmune, the company has a number of other Yδ T cell candidates in development for various cancer indications.

One of the most significant recent advances from TC Biopharm is the development of its candidate TCB008, which is under investigation in the Phase 2 ACHIEVE trial. The firm reported in June 2025 that the first patient in Cohort B, who had relapsed previously with detectable MRD, reached complete molecular remission following two doses. A lack of detectable NPM1 transcripts after treatment signifies a profound and lasting response, which identifies TCB008 as a promising post-remission therapy for blood cancers. This achievement demarcates the potent, targeted immune function of Yδ T cells and substantiates their role as a new therapeutic strategy.

Globally, most of the research studies on Yδ T cells remains on hematologic malignancies, and there are fewer programs directed at solid tumors. This is partly a result of the more sophisticated microenvironments and the immune evasion mechanisms utilized by solid cancers. However, attempts are being made to apply Yδ T cell treatments to these more difficult contexts. Geographically, US-based players dominate the Yδ T cell therapy market, followed by increasing numbers of Chinese firms. These regions have made heavy investment in cell therapy facilities and technology, facilitating quicker translation from bench to bedside.

Moving forward, the prospects for Yδ T cell therapy are bright but will necessitate continued clinical validation, most importantly in solid tumors. With advances in manufacturing technologies and biomarker-driven strategies, the use of Yδ T cells may extend to more types of cancers. With leaders such as TC Biopharm at the forefront, the field is on track to provide life changing treatments for critical unmet needs in cancer domain.

1. Introduction To Gamma Delta T Cell Therapy

1.1 Emerging Role of T Cell Based Immunotherapies
1.2 Overview of Gamma Delta T Cell Therapy
1.3 Gamma Delta T Cell Therapy v/s Conventional Therapies

2. Role of Gamma Delta T Cells in Cancer

2.1 Gamma Delta T Cells in Cancer Progression
2.2 Anti Tumor Activity of Gamma Delta T Cells
2.3 Adopted Approaches for Gamma Delta T Cell Therapy

3. Advanced Combination Strategies In Gamma Delta T Cell Therapy

4. Gamma Delta T Cell Therapy Market Overview

4.1 Current Market Scenario
4.2 Future R&D & Commercial Opportunities
4.3 Market Potential of Gamma Delta T Cell Therapy Market
4.4 Technology Platforms For Gamma Delta T Cell Therapy
4.5 Favorable Market Growth Parameters
4.6 Key Challenges To Overcome For Future Growth

5. Global Gamma Delta T Cell Therapy Clinical Trials Overview

5.1 By Phase
5.2 By Country
5.3 By Company
5.4 By Indication
5.5 By Priority Status

6. Global Gamma Delta T Cell Therapy Clinical Trials Insight By Company, Country, Indication & Phase

6.1 Research
6.2 Preclinical
6.3 Phase I
6.4 Phase I/II
6.5 Phase II
6.6 Phase II/III

7. Gamma Delta T Cell Therapy In Leukemia

7.1 Ongoing Clinical Research & Development Trends
7.2 Future Market Opportunity of Gamma Delta T Cells In Leukemia

8. Gamma Delta T Cell Therapy In Lung Cancer

8.1 Ongoing Clinical Research & Development Trends
8.2 Future Market Opportunity of Gamma Delta T Cell Therapy In Lung Cancer

9. Gamma Delta T Cells In Breast Cancer

9.1 Ongoing Clinical Research & Development Trends
9.2 Future Market Opportunity of Gamma Delta T Cell Therapy In Breast Cancer

10. Gamma Delta T Cells in Colorectal Cancer

10.1 Ongoing Clinical Research & Development Trends
10.2 Future Market Potential of Gamma Delta T Cell Therapy in Colorectal Cancer

11. Gamma Delta T Cells In Pancreatic Cancer

11.1 Ongoing Clinical Research & Development Trends
11.2 Future Market Potential of Gamma Delta Therapy In Pancreatic Cancer

12. Gamma Delta T Cells In Lymphoma

12.1 Ongoing Clinical Research & Development Trends
12.2 Future Market Potential of Gamma Delta Therapy In Lymphoma

13. Gamma Delta T Cell Therapy In Brain Tumors

13.1 Research & Development In Brain Tumors
13.2 Future Market Potential of Gamma Delta Therapy In Brain Tumors

14. Gamma Delta T Cell Therapy In Head & Neck Cancer

14.1 Research & Development In Head & Neck Cancer
14.2 Future Market Potential of Gamma Delta Therapy In Head & Neck Cancer

15. Competitive Landscape

15.1 Acepodia
15.2 Adicet
15.3 Appia Bio
15.4 Cytomed Therapeutics
15.5 Century Therapeutics
15.6 Expression Therapeutics
15.7 Immatics
15.8 IN8bio
15.9 JY BioMed
15.10 Legend Biotech
15.11 Luminary Therapeutics
15.12 PhosphoGam
15.13 Takeda
15.14 TC Biopharm
15.15 ViGenCell

がんのガンマ・デルタT細胞療法の世界市場：市場動向、技術プラットフォーム、臨床試験の見通し（2031年）

Global Gamma Delta T Cell Cancer Therapy Market Trends, Technology Platforms & Clinical Trials Outlook 2031

目次

第1章ガンマ・デルタT細胞療法のイントロダクション

第2章がんにおけるガンマ・デルタT細胞の役割

第3章ガンマ・デルタT細胞療法における高度な併用戦略

第4章ガンマ・デルタT細胞療法市場概要

第5章世界のガンマ・デルタT細胞療法の臨床試験の概要

第6章世界ガンマ・デルタT細胞療法臨床試験の洞察、企業、国、適応症、相別

第7章白血病におけるガンマ・デルタT細胞療法

第8章肺がんにおけるガンマ・デルタT細胞療法

第9章乳がんにおけるガンマ・デルタT細胞

第10章大腸がんにおけるガンマ・デルタT細胞

第11章膵臓がんにおけるガンマ・デルタT細胞

第12章リンパ腫におけるガンマ・デルタT細胞

第13章脳腫瘍におけるガンマ・デルタT細胞療法

第14章頭頸部がんにおけるガンマ・デルタT細胞療法

第15章競合情勢

List of Figures

List of Tables

Table of Contents

1. Introduction To Gamma Delta T Cell Therapy

2. Role of Gamma Delta T Cells in Cancer

3. Advanced Combination Strategies In Gamma Delta T Cell Therapy

4. Gamma Delta T Cell Therapy Market Overview

5. Global Gamma Delta T Cell Therapy Clinical Trials Overview

6. Global Gamma Delta T Cell Therapy Clinical Trials Insight By Company, Country, Indication & Phase

7. Gamma Delta T Cell Therapy In Leukemia

8. Gamma Delta T Cell Therapy In Lung Cancer

9. Gamma Delta T Cells In Breast Cancer

10. Gamma Delta T Cells in Colorectal Cancer

11. Gamma Delta T Cells In Pancreatic Cancer

12. Gamma Delta T Cells In Lymphoma

13. Gamma Delta T Cell Therapy In Brain Tumors

14. Gamma Delta T Cell Therapy In Head & Neck Cancer

15. Competitive Landscape

がんのガンマ・デルタT細胞療法の世界市場：市場動向、技術プラットフォーム、臨床試験の見通し（2031年）

Global Gamma Delta T Cell Cancer Therapy Market Trends, Technology Platforms & Clinical Trials Outlook 2031

目次

第1章 ガンマ・デルタT細胞療法のイントロダクション

第2章 がんにおけるガンマ・デルタT細胞の役割

第3章 ガンマ・デルタT細胞療法における高度な併用戦略

第4章 ガンマ・デルタT細胞療法市場概要

第5章 世界のガンマ・デルタT細胞療法の臨床試験の概要

第6章 世界ガンマ・デルタT細胞療法臨床試験の洞察、企業、国、適応症、相別

第7章 白血病におけるガンマ・デルタT細胞療法

第8章 肺がんにおけるガンマ・デルタT細胞療法

第9章 乳がんにおけるガンマ・デルタT細胞

第10章 大腸がんにおけるガンマ・デルタT細胞

第11章 膵臓がんにおけるガンマ・デルタT細胞

第12章 リンパ腫におけるガンマ・デルタT細胞

第13章 脳腫瘍におけるガンマ・デルタT細胞療法

第14章 頭頸部がんにおけるガンマ・デルタT細胞療法

第15章 競合情勢

List of Figures

List of Tables

Table of Contents

1. Introduction To Gamma Delta T Cell Therapy

2. Role of Gamma Delta T Cells in Cancer

3. Advanced Combination Strategies In Gamma Delta T Cell Therapy

4. Gamma Delta T Cell Therapy Market Overview

5. Global Gamma Delta T Cell Therapy Clinical Trials Overview

6. Global Gamma Delta T Cell Therapy Clinical Trials Insight By Company, Country, Indication & Phase

7. Gamma Delta T Cell Therapy In Leukemia

8. Gamma Delta T Cell Therapy In Lung Cancer

9. Gamma Delta T Cells In Breast Cancer

10. Gamma Delta T Cells in Colorectal Cancer

11. Gamma Delta T Cells In Pancreatic Cancer

12. Gamma Delta T Cells In Lymphoma

13. Gamma Delta T Cell Therapy In Brain Tumors

14. Gamma Delta T Cell Therapy In Head & Neck Cancer

15. Competitive Landscape

第1章ガンマ・デルタT細胞療法のイントロダクション

第2章がんにおけるガンマ・デルタT細胞の役割

第3章ガンマ・デルタT細胞療法における高度な併用戦略

第4章ガンマ・デルタT細胞療法市場概要

第5章世界のガンマ・デルタT細胞療法の臨床試験の概要

第6章世界ガンマ・デルタT細胞療法臨床試験の洞察、企業、国、適応症、相別

第7章白血病におけるガンマ・デルタT細胞療法

第8章肺がんにおけるガンマ・デルタT細胞療法

第9章乳がんにおけるガンマ・デルタT細胞

第10章大腸がんにおけるガンマ・デルタT細胞

第11章膵臓がんにおけるガンマ・デルタT細胞

第12章リンパ腫におけるガンマ・デルタT細胞

第13章脳腫瘍におけるガンマ・デルタT細胞療法

第14章頭頸部がんにおけるガンマ・デルタT細胞療法

第15章競合情勢